Sign Out
Pregnancy: There are no data from the use of gadobenate dimeglumine in pregnant women. Animal studies have shown reproductive toxicity at repeated high doses (see Pharmacology: Toxicology: Preclinical safety data under Actions). MultiHance should not be used during pregnancy unless the clinical condition of the woman requires use of gadobenate dimeglumine.
Lactation: Gadolinium containing contrast agents are excreted into breast milk in very small amounts (see Pharmacology: Toxicology: Preclinical safety data under Actions). At clinical doses, no effects on the infant are anticipated due to the small amount excreted into milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration of MultiHance should be at the discretion of the doctor and lactating mother.
